{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:46:28Z","timestamp":1792698388330,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"DOI":"10.1007\/s11606-026-10829-1","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:15:32Z","timestamp":1792696532000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictors of Newly Prescribed Medications for Alcohol Use Disorder Among Hospitalized Adults: A Retrospective Cohort Study"],"prefix":"10.1007","author":[{"given":"Neela","family":"Nataraj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen A.","family":"Colbenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell R.","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8061-283X","authenticated-orcid":false,"given":"John T.","family":"Ratelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"10829_CR1","unstructured":"Alcohol Use Disorder (AUD) in the United States: Age Groups and Demographic Characteristics | National Institute on Alcohol Abuse and Alcoholism (NIAAA). https:\/\/www.niaaa.nih.gov\/alcohols-effects-health\/alcohol-topics\/alcohol-facts-and-statistics\/alcohol-use-disorder-aud-united-states-age-groups-and-demographic-characteristics. Accessed 14 Nov 2025."},{"issue":"4","key":"10829_CR2","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1001\/jama.2024.21503","volume":"333","author":"V Sethi","year":"2025","unstructured":"Sethi V, Bataller R, Liu H, Ruppert KM, Molinari M. Trends in Hospitalizations and Liver Transplants Associated With Alcohol-Induced Liver Disease. JAMA. 2025;333(4):345-347. https:\/\/doi.org\/10.1001\/jama.2024.21503.","journal-title":"JAMA."},{"issue":"10","key":"10829_CR3","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1007\/s11606-021-07069-w","volume":"37","author":"LW Suen","year":"2022","unstructured":"Suen LW, Makam AN, Snyder HR, et al. National Prevalence of Alcohol and Other Substance Use Disorders Among Emergency Department Visits and Hospitalizations: NHAMCS 2014\u20132018. J Gen Intern Med. 2022;37(10):2420-2428. https:\/\/doi.org\/10.1007\/s11606-021-07069-w.","journal-title":"J Gen Intern Med."},{"key":"10829_CR4","doi-asserted-by":"publisher","unstructured":"Wani RJ, Tak HJ, Watanabe-Galloway S, et al. Predictors and Costs of 30-Day Readmissions After Index Hospitalizations for Alcohol-Related Disorders in U.S. Adults. Alcohol Clin Exp Res. 2019;43(5):857\u2013868. https:\/\/doi.org\/10.1111\/acer.14021.","DOI":"10.1111\/acer.14021"},{"issue":"3","key":"10829_CR5","doi-asserted-by":"publisher","first-page":"e243387","DOI":"10.1001\/jamanetworkopen.2024.3387","volume":"7","author":"EY Bernstein","year":"2024","unstructured":"Bernstein EY, Baggett TP, Trivedi S, Herzig SJ, Anderson TS. Outcomes After Initiation of Medications for Alcohol Use Disorder at Hospital Discharge. JAMA Netw Open. 2024;7(3):e243387. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.3387.","journal-title":"JAMA Netw Open."},{"key":"10829_CR6","doi-asserted-by":"publisher","unstructured":"Calabrese J, Brown J, Hasan M, Neuhut S, Jo Y. Hospital Readmission in Alcohol Use Disorder Patients: The Role of Anti-Craving Medications and Discharge Disposition. HCA Healthc J Med. 3(2):39\u201345. https:\/\/doi.org\/10.36518\/2689-0216.1243.","DOI":"10.36518\/2689-0216.1243"},{"issue":"17","key":"10829_CR7","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/jama.2023.19761","volume":"330","author":"M McPheeters","year":"2023","unstructured":"McPheeters M, O\u2019Connor EA, Riley S, et al. Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis. JAMA. 2023;330(17):1653-1665. https:\/\/doi.org\/10.1001\/jama.2023.19761.","journal-title":"JAMA."},{"issue":"7","key":"10829_CR8","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/j.1360-0443.2004.00763.x","volume":"99","author":"B Carmen","year":"2004","unstructured":"Carmen B, Angeles M, Ana M, Mar\u00eda AJ. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction. 2004;99(7):811-828. https:\/\/doi.org\/10.1111\/j.1360-0443.2004.00763.x.","journal-title":"Addiction."},{"issue":"12","key":"10829_CR9","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1002\/hep4.2080","volume":"6","author":"D Ayyala","year":"2022","unstructured":"Ayyala D, Bottyan T, Tien C, et al. Naltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease. Hepatol Commun. 2022;6(12):3433-3442. https:\/\/doi.org\/10.1002\/hep4.2080.","journal-title":"Hepatol Commun."},{"issue":"7","key":"10829_CR10","doi-asserted-by":"publisher","first-page":"101095","DOI":"10.1016\/j.jhepr.2024.101095","volume":"6","author":"R Thompson","year":"2024","unstructured":"Thompson R, Taddei T, Kaplan D, Rabiee A. Safety of naltrexone in patients with cirrhosis. JHEP Rep Innov Hepatol. 2024;6(7):101095. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101095.","journal-title":"JHEP Rep Innov Hepatol."},{"key":"10829_CR11","unstructured":"Varshney M, Alla M, Sm S, Kumar G, Arora V, Sarin S. ANALYZING NEW ONSET HEPATIC DECOMPENSATION AND LONG TERM ABSTINENCE\/CRAVING IN PATIENTS WITH ALCOHOL ASSOCIATED LIVER DISEASES(AALD): A DOUBLE BLIND RANDOMIZED CONTROL TRIAL (RCT) FOR EFFECTIVENESS OF SELF ADMINISTERED 12 WEEKS 50 MG ORAL NALTREXONE VERSU | AASLD. In: The Liver Meeting 2023. 2023. https:\/\/www.aasld.org\/the-liver-meeting\/analyzing-new-onset-hepatic-decompensation-and-long-term-abstinencecraving. Accessed 7 Feb 2026."},{"issue":"4","key":"10829_CR12","doi-asserted-by":"publisher","first-page":"e0093","DOI":"10.1097\/HC9.0000000000000093","volume":"7","author":"A Rabiee","year":"2023","unstructured":"Rabiee A, Mahmud N, Falker C, Garcia-Tsao G, Taddei T, Kaplan DE. Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis. Hepatol Commun. 2023;7(4):e0093. https:\/\/doi.org\/10.1097\/HC9.0000000000000093.","journal-title":"Hepatol Commun."},{"issue":"12","key":"10829_CR13","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1007\/s11606-024-09228-1","volume":"40","author":"SL Calcaterra","year":"2025","unstructured":"Calcaterra SL, Mann S, Grimm E, Keniston A, Saunders S. Perspectives of In-Hospital Intramuscular Naltrexone and Oral Medications for Alcohol Use Disorder: A Study of Addiction Clinicians and Hospitalized Patients. J Gen Intern Med. 2025;40(12):2981-2988. https:\/\/doi.org\/10.1007\/s11606-024-09228-1.","journal-title":"J Gen Intern Med."},{"key":"10829_CR14","doi-asserted-by":"publisher","first-page":"209831","DOI":"10.1016\/j.josat.2025.209831","volume":"180","author":"BT Hilton","year":"2026","unstructured":"Hilton BT, Haidamus MA, Votaw VR, et al. Stigma and knowledge about medications for alcohol use disorder among treatment-seeking adults. J Subst Use Addict Treat. 2026;180:209831. https:\/\/doi.org\/10.1016\/j.josat.2025.209831.","journal-title":"J Subst Use Addict Treat."},{"issue":"8","key":"10829_CR15","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.7326\/M23-0641","volume":"176","author":"EY Bernstein","year":"2023","unstructured":"Bernstein EY, Baggett TP, Trivedi S, Herzig SJ, Anderson TS. Pharmacologic Treatment Initiation Among Medicare Beneficiaries Hospitalized With Alcohol Use Disorder. Ann Intern Med. 2023;176(8):1137-1139. https:\/\/doi.org\/10.7326\/M23-0641.","journal-title":"Ann Intern Med."},{"key":"10829_CR16","doi-asserted-by":"publisher","unstructured":"Bernstein EY, Lebin JA, Hoppe J, et al. Variation in initiation of medications for alcohol use disorder during alcohol withdrawal hospitalizations in a large health system: A retrospective cohort study. J Hosp Med. n\/a(n\/a). https:\/\/doi.org\/10.1002\/jhm.70201.","DOI":"10.1002\/jhm.70201"},{"issue":"5","key":"10829_CR17","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/ADM.0000000000000611","volume":"14","author":"H Englander","year":"2020","unstructured":"Englander H, King C, Nicolaidis C, et al. Predictors of Opioid and Alcohol Pharmacotherapy Initiation at Hospital Discharge Among Patients Seen by an Inpatient Addiction Consult Service. J Addict Med. 2020;14(5):415-422. https:\/\/doi.org\/10.1097\/ADM.0000000000000611.","journal-title":"J Addict Med."},{"issue":"3","key":"10829_CR18","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s11606-017-4202-z","volume":"33","author":"EC Williams","year":"2018","unstructured":"Williams EC, Achtmeyer CE, Young JP, et al. Barriers to and Facilitators of Alcohol Use Disorder Pharmacotherapy in Primary Care: A Qualitative Study in Five VA Clinics. J Gen Intern Med. 2018;33(3):258-267. https:\/\/doi.org\/10.1007\/s11606-017-4202-z.","journal-title":"J Gen Intern Med."},{"issue":"11","key":"10829_CR19","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1016\/j.cgh.2020.10.026","volume":"19","author":"GY Im","year":"2021","unstructured":"Im GY, Mellinger JL, Winters A, et al. Provider Attitudes and Practices for Alcohol Screening, Treatment, and Education in Patients With Liver Disease: A Survey From the American Association for the Study of Liver Diseases Alcohol-Associated Liver Disease Special Interest Group. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2021;19(11):2407-2416.e8. https:\/\/doi.org\/10.1016\/j.cgh.2020.10.026.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc."},{"key":"10829_CR20","doi-asserted-by":"publisher","first-page":"108090","DOI":"10.1016\/j.drugalcdep.2020.108090","volume":"213","author":"PJ Joudrey","year":"2020","unstructured":"Joudrey PJ, Oldfield BJ, Yonkers KA, O\u2019Connor PG, Berland G, Edelman EJ. Inpatient adoption of medications for alcohol use disorder: A mixed-methods formative evaluation involving key stakeholders. Drug Alcohol Depend. 2020;213:108090. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108090.","journal-title":"Drug Alcohol Depend."},{"key":"10829_CR21","doi-asserted-by":"publisher","unstructured":"Noverati N, Rakiewicz T, Chism K, Halegoua-DeMarzio D, Zavodnick J. Understanding Barriers to Prescribing Pharmacotherapy for Alcohol Use Disorder: A Shared Responsibility. Off J Am Coll Gastroenterol ACG. 2022;117(10S):e937. https:\/\/doi.org\/10.14309\/01.ajg.0000861844.41170.03.","DOI":"10.14309\/01.ajg.0000861844.41170.03"},{"key":"10829_CR22","doi-asserted-by":"publisher","first-page":"856938","DOI":"10.3389\/fpsyt.2022.856938","volume":"13","author":"JG Leung","year":"2022","unstructured":"Leung JG, Narayanan PP, Markota M, et al. Assessing Naltrexone Prescribing and Barriers to Initiation for Alcohol Use Disorder: A Multidisciplinary, Multisite Survey. Front Psychiatry. 2022;13:856938. https:\/\/doi.org\/10.3389\/fpsyt.2022.856938.","journal-title":"Multisite Survey. Front Psychiatry."},{"key":"10829_CR23","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3389\/fpsyt.2016.00182","volume":"7","author":"C Ponce Martinez","year":"2016","unstructured":"Ponce Martinez C, Vakkalanka P, Ait-Daoud N. Pharmacotherapy for Alcohol Use Disorders: Physicians\u2019 Perceptions and Practices. Front Psychiatry. 2016;7:182. https:\/\/doi.org\/10.3389\/fpsyt.2016.00182.","journal-title":"Front Psychiatry."},{"key":"10829_CR24","doi-asserted-by":"publisher","unstructured":"Sokol R, Ahern J, Pleman B, et al. An Evaluation of STFM\u2019s National Addiction Curriculum. Fam Med. 2023;55(6):362\u2013366. https:\/\/doi.org\/10.22454\/FamMed.2023.340020.","DOI":"10.22454\/FamMed.2023.340020"},{"issue":"1","key":"10829_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pop.2022.10.009","volume":"50","author":"J Petrides","year":"2023","unstructured":"Petrides J. Motivational Interviewing in Primary-Care: Substance Use Disorders beyond AUDIT\/DAST. Prim Care. 2023;50(1):1-10. https:\/\/doi.org\/10.1016\/j.pop.2022.10.009.","journal-title":"Prim Care."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10829-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-026-10829-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10829-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:15:33Z","timestamp":1792696533000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-026-10829-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":25,"alternative-id":["10829"],"URL":"https:\/\/doi.org\/10.1007\/s11606-026-10829-1","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"8 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was deemed exempt by the Mayo Clinic institutional review board (IRB # 24-002060) due to the use of retrospectively collected, de-identified data with no direct participant contact. Informed consent was waived.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they do not have a conflict of interest.","order":2,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Clinical Trial Number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}